Download Here
Journal: The Pharma Innovation
Volume: 1
Issue: 2
Author: K.P. Sampath Kumar*, Debjit bhowmik, Shweta Srivastava, Shravan Paswan, Amit sankar DuttaVolume: 1
Issue: 2
Abstract: India, the world’s second most populous country, now has
more people with type 2 diabetes (more than 50 million) than any other
nation. With India having the highest number of diabetic patients in
the world, the sugar disease is posing an enormous health problem in
the country. Calling India the diabetes capital of the world, the
International Journal of Diabetes in Developing Countries says that
there is alarming rise in. According to a WHO fact sheet on diabetes,
2004 recorded an estimated 3.4 million deaths due to consequences of
high blood sugar. WHO also estimates that 80 per cent of diabetes
deaths occur in low- and middle-income countries and projects that such
deaths will double between 2005 and 2030. A glance at statistics from
Global Data proves one point: that the two countries having the highest
diabetes prevalence (India and China) score quite low when it comes to
the expenditure on the disease. In fact, India's expenditure on
diabetes does not figure among the top 10 countries at all. The
situation is compounded by the fact that diabetes is one of the most
costly health problems in the world. It is points out that healthcare
expenditure on diabetes accounted for 11.6 per cent of the total
healthcare expenditure worldwide in 2010. Diabetes also imposes large
economic burdens in the form of lost productivity and foregone economic
growth. It has been estimated that the global burden of type 2 diabetes
mellitus (T2DM) for 2010 would be 285million people (2010) which is
projected to increase to 438 million in 2030; a 65 % increase .
Similarly, for India this increase is estimated to be 58%, from 51
million people in 2010 to 87 million in 2030. The impacts of T2DM are
considerable: as a lifelong disease, it increases morbidity and
mortality and decreases the quality of life. At the same time, the
disease and its complications cause a heavy economic burden for diabetic
patients themselves, their families and society. A better
understanding about the cause of a predisposition of Indians to get
T2DM is necessary for future planning of healthcare, policy and
delivery in order to ensure that the burdens of disease are addressed.
